Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Natural and in vitro-generated regulatory T-cell subsets differentially modulate phenotype and drug response in K562 leukemic cells.

Cancer treatment and research communications - 1 Jan 2026

Ostapchuk Yekaterina O, Kan Sofiya A, Lushova Anzhelika V, Tleulieva Raikhan, Abdolla Nurshat, Kali Aikyn, Perfilyeva Yuliya V

Abstract excerpt

Regulatory T cells (Tregs) are key mediators of immune suppression in cancer and are frequently elevated in hematologic malignancies, including acute and chronic leukemias, however, their role in modulating the leukemic cell phenotype and therapy response remains unclear. This study investigated whether natural Tregs (nTregs), in vitro-generated CD4+CD25+Foxp3+ Tregs (iTregs), and type 1 regulatory T (Tr1) cells...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Coculture Techniques
Share to Daunorubicin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Gemcitabine

Share to K562 Cells

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to T-Lymphocytes, Regulatory

Share to Transforming Growth Factor beta1

Source

Identifiers

PMID: 42150390
DOI: 10.1016/j.ctarc.2026.101244

Genes

ABCG2
CD24
CD34
CD4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Natural and in vitro-generated regulatory T-cell subsets differentially modulate phenotype and drug response in K562 leukemic cells.PMID 42150390Read ↗

Regulatory T cell therapy for Graft-versus-Host DiseaseSemantic proximity Read ↗

Regulatory T cells in solid organ transplantationSemantic proximity Read ↗

Immunosuppressive Treg cells acquire the phenotype of effector-T cells in chronic lymphocytic leukemia patients.Semantic proximity Read ↗

Targeting T regulatory (T reg ) cells in immunotherapy-resistant cancersSemantic proximity Read ↗

Regulatory T Cell Therapy of Graft-versus-Host Disease: Advances and ChallengesSemantic proximity Read ↗

Systematic Elucidation and Pharmacological Targeting of Tumor-Infiltrating Regulatory T Cell Master RegulatorsSemantic proximity Read ↗

Induced and natural regulatory T cells in human cancer.Semantic proximity Read ↗

Genetically modified and unmodified cellular approaches to enhance graft versus leukemia effect, without increasing graft versus host disease: the use of allogeneic cytokine-induced killer cellsSemantic proximity Read ↗

Interleukin-2 and Tretinoin for Myeloproliferative Neoplasms and to Target Type 1 Calreticulin-Driven Neoplasms: Advancements in Immune Regenerative Medicine.Semantic proximity Read ↗

Clinical significance of Treg cell frequency in acute myeloid leukemia.Semantic proximity Read ↗

Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer.Semantic proximity Read ↗

Peripheral blood-derived, γ9δ2 t cell-enriched cell lines from glioblastoma multiforme patients exert anti-tumoral effects in vitro.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.